Cargando…
The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study
BACKGROUND: There are limited data available on whether drug-induced hepatotoxicity (DIH) affects the clinical outcomes of tuberculosis (TB) treatment. We explored the effects of DIH on the clinical course and outcomes of pulmonary TB. METHODS: In this retrospective cohort study, we included patient...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915938/ https://www.ncbi.nlm.nih.gov/pubmed/31842883 http://dx.doi.org/10.1186/s12931-019-1256-y |
_version_ | 1783480127108153344 |
---|---|
author | Song, Jin Hwa Yoon, Seo-Young Park, Tae Yun Heo, Eun Young Kim, Deog Kyeom Chung, Hee Soon Lee, Jung-Kyu |
author_facet | Song, Jin Hwa Yoon, Seo-Young Park, Tae Yun Heo, Eun Young Kim, Deog Kyeom Chung, Hee Soon Lee, Jung-Kyu |
author_sort | Song, Jin Hwa |
collection | PubMed |
description | BACKGROUND: There are limited data available on whether drug-induced hepatotoxicity (DIH) affects the clinical outcomes of tuberculosis (TB) treatment. We explored the effects of DIH on the clinical course and outcomes of pulmonary TB. METHODS: In this retrospective cohort study, we included patients with culture-proven pulmonary TB treated in a tertiary hospital from 2013 to 2016. DIH was defined as proposed by the official American Thoracic Society statement. We compared the clinical outcomes of DIH and non-DIH patients. RESULTS: Between January 1, 2013 and December 31, 2016, a total of 168 TB patients were included, and 20 (11.9%) were diagnosed with DIH. These patients were significantly older, had a higher Charlson Comorbidity Index score, exhibited more chronic liver disease, included more chronic alcoholics, and had a lower body mass index than non-DIH patients. We found no significant differences between DIH and non-DIH patients in the 2-month sputum culture conversion rate, the time to sputum culture conversion, treatment outcomes, or total treatment duration. However, the ratio of treatment interruption time to total treatment duration and the proportion of hepatotonic users were significantly higher among DIH patients. CONCLUSION: DIH development during TB treatment does not significantly affect the clinical outcomes of pulmonary TB. However, treatment interruption caused by DIH may increase the risks of future relapse and acquired resistance. Further study is needed. |
format | Online Article Text |
id | pubmed-6915938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69159382019-12-30 The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study Song, Jin Hwa Yoon, Seo-Young Park, Tae Yun Heo, Eun Young Kim, Deog Kyeom Chung, Hee Soon Lee, Jung-Kyu Respir Res Research BACKGROUND: There are limited data available on whether drug-induced hepatotoxicity (DIH) affects the clinical outcomes of tuberculosis (TB) treatment. We explored the effects of DIH on the clinical course and outcomes of pulmonary TB. METHODS: In this retrospective cohort study, we included patients with culture-proven pulmonary TB treated in a tertiary hospital from 2013 to 2016. DIH was defined as proposed by the official American Thoracic Society statement. We compared the clinical outcomes of DIH and non-DIH patients. RESULTS: Between January 1, 2013 and December 31, 2016, a total of 168 TB patients were included, and 20 (11.9%) were diagnosed with DIH. These patients were significantly older, had a higher Charlson Comorbidity Index score, exhibited more chronic liver disease, included more chronic alcoholics, and had a lower body mass index than non-DIH patients. We found no significant differences between DIH and non-DIH patients in the 2-month sputum culture conversion rate, the time to sputum culture conversion, treatment outcomes, or total treatment duration. However, the ratio of treatment interruption time to total treatment duration and the proportion of hepatotonic users were significantly higher among DIH patients. CONCLUSION: DIH development during TB treatment does not significantly affect the clinical outcomes of pulmonary TB. However, treatment interruption caused by DIH may increase the risks of future relapse and acquired resistance. Further study is needed. BioMed Central 2019-12-16 2019 /pmc/articles/PMC6915938/ /pubmed/31842883 http://dx.doi.org/10.1186/s12931-019-1256-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Song, Jin Hwa Yoon, Seo-Young Park, Tae Yun Heo, Eun Young Kim, Deog Kyeom Chung, Hee Soon Lee, Jung-Kyu The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study |
title | The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study |
title_full | The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study |
title_fullStr | The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study |
title_full_unstemmed | The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study |
title_short | The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study |
title_sort | clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915938/ https://www.ncbi.nlm.nih.gov/pubmed/31842883 http://dx.doi.org/10.1186/s12931-019-1256-y |
work_keys_str_mv | AT songjinhwa theclinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT yoonseoyoung theclinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT parktaeyun theclinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT heoeunyoung theclinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT kimdeogkyeom theclinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT chungheesoon theclinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT leejungkyu theclinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT songjinhwa clinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT yoonseoyoung clinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT parktaeyun clinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT heoeunyoung clinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT kimdeogkyeom clinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT chungheesoon clinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy AT leejungkyu clinicalimpactofdruginducedhepatotoxicityonantituberculosistherapyacasecontrolstudy |